Develops glucose monitoring systems for diabetes management, focusing on continuous glucose monitoring.
Senseonics Holdings, Inc. is a leading medical technology innovator specializing in the development and global distribution of continuous glucose monitoring (CGM) systems tailored for individuals managing diabetes across the United States, Europe, the Middle East, and Africa. Central to its product lineup are Eversense and Eversense XL, revolutionary implantable CGM systems designed to monitor glucose levels through an under-the-skin sensor. These systems integrate seamlessly with a removable, rechargeable smart transmitter and an intuitive mobile application, offering real-time data for up to six months, enhancing diabetes management and patient convenience.
The company's commitment to advancing diabetes care extends through strategic partnerships and collaborations, including an agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc., established in 1996 and headquartered in Germantown, Maryland, operates through a robust network of distributors and strategic fulfillment partners, ensuring broad accessibility of its cutting-edge CGM technology to healthcare providers and patients alike.
With a legacy rooted in innovation and a relentless pursuit of improving patient outcomes, Senseonics Holdings continues to redefine standards in diabetes management through its state-of-the-art CGM solutions. By leveraging its expertise and expanding global presence, the company remains dedicated to empowering individuals with diabetes with the tools needed for effective, personalized glucose monitoring and control.